Case of fulminant type 1 diabetes induced by the anti-programmed death-ligand 1 antibody, avelumab. 2019

Yui Shibayama, and Hiraku Kameda, and Shoichiro Ota, and Kazuhisa Tsuchida, and Kyu Yong Cho, and Akinobu Nakamura, and Hideaki Miyoshi, and Tatsuya Atsumi
Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.

With the expansive use of immune checkpoint inhibitors, the frequency of immune-related adverse events, including autoimmune type 1 diabetes, has been exponentially increased. The anti-programmed death-ligand 1 antibody, avelumab, has recently been approved for metastatic Merkel cell carcinoma therapy. Here, we report a patient that developed fulminant type 1 diabetes during avelumab treatment. An 81-year-old woman with no history of diabetes received avelumab for metastatic Merkel cell carcinoma. Elevated plasma glucose level (483 mg/dL), hemoglobin A1c level (7.5%) and ketosis were observed after 10 courses of avelumab without any symptoms related to hyperglycemia. As the laboratory tests showed insulin depletion, we diagnosed her with fulminant type 1 diabetes induced by avelumab. This is the first reported case of avelumab-induced type 1 diabetes, illustrating the necessity for close monitoring of glycemic control during avelumab therapy, as well as other immune checkpoint inhibitors.

UI MeSH Term Description Entries
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D003922 Diabetes Mellitus, Type 1 A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence. Diabetes Mellitus, Brittle,Diabetes Mellitus, Insulin-Dependent,Diabetes Mellitus, Juvenile-Onset,Diabetes Mellitus, Ketosis-Prone,Diabetes Mellitus, Sudden-Onset,Diabetes, Autoimmune,IDDM,Autoimmune Diabetes,Diabetes Mellitus, Insulin-Dependent, 1,Diabetes Mellitus, Type I,Insulin-Dependent Diabetes Mellitus 1,Juvenile-Onset Diabetes,Type 1 Diabetes,Type 1 Diabetes Mellitus,Brittle Diabetes Mellitus,Diabetes Mellitus, Insulin Dependent,Diabetes Mellitus, Juvenile Onset,Diabetes Mellitus, Ketosis Prone,Diabetes Mellitus, Sudden Onset,Diabetes, Juvenile-Onset,Diabetes, Type 1,Insulin Dependent Diabetes Mellitus 1,Insulin-Dependent Diabetes Mellitus,Juvenile Onset Diabetes,Juvenile-Onset Diabetes Mellitus,Ketosis-Prone Diabetes Mellitus,Sudden-Onset Diabetes Mellitus
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D012878 Skin Neoplasms Tumors or cancer of the SKIN. Cancer of Skin,Skin Cancer,Cancer of the Skin,Neoplasms, Skin,Cancer, Skin,Cancers, Skin,Neoplasm, Skin,Skin Cancers,Skin Neoplasm
D015266 Carcinoma, Merkel Cell A carcinoma arising from MERKEL CELLS located in the basal layer of the epidermis and occurring most commonly as a primary neuroendocrine carcinoma of the skin. Merkel cells are tactile cells of neuroectodermal origin and histologically show neurosecretory granules. The skin of the head and neck are a common site of Merkel cell carcinoma, occurring generally in elderly patients. (Holland et al., Cancer Medicine, 3d ed, p1245) Merkel Cell Tumor,Merkel Cell Cancer,Merkel Cell Carcinoma,Merkle Tumors,Cancer, Merkel Cell,Cell Cancer, Merkel,Tumor, Merkel Cell,Tumors, Merkle
D060890 B7-H1 Antigen An inhibitory B7 antigen that contains V-type and C2 type immunoglobulin domains. It has specificity for the T-CELL receptor PROGRAMMED CELL DEATH 1 PROTEIN and provides negative signals that control and inhibit T-cell responses. It is found at higher than normal levels on tumor cells, suggesting its potential role in TUMOR IMMUNE EVASION. Antigens, CD274,PD-L1 Protein,Programmed Cell Death 1 Ligand 1 Protein,Programmed Death Ligand 1,B7-H1 Immune Costimulatory Protein,B7H1 Immune Costimulatory Protein,CD274 Antigen,PD-L1 Costimulatory Protein,Programmed Cell Death 1 Ligand 1,Antigen, B7-H1,Antigen, CD274,B7 H1 Antigen,B7 H1 Immune Costimulatory Protein,CD274 Antigens,Costimulatory Protein, PD-L1,PD L1 Costimulatory Protein,PD L1 Protein
D061067 Antibodies, Monoclonal, Humanized Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab. Antibodies, Humanized,Humanized Antibodies

Related Publications

Yui Shibayama, and Hiraku Kameda, and Shoichiro Ota, and Kazuhisa Tsuchida, and Kyu Yong Cho, and Akinobu Nakamura, and Hideaki Miyoshi, and Tatsuya Atsumi
October 2021, Zhonghua nei ke za zhi,
Yui Shibayama, and Hiraku Kameda, and Shoichiro Ota, and Kazuhisa Tsuchida, and Kyu Yong Cho, and Akinobu Nakamura, and Hideaki Miyoshi, and Tatsuya Atsumi
June 2016, The Tohoku journal of experimental medicine,
Yui Shibayama, and Hiraku Kameda, and Shoichiro Ota, and Kazuhisa Tsuchida, and Kyu Yong Cho, and Akinobu Nakamura, and Hideaki Miyoshi, and Tatsuya Atsumi
March 2018, Journal of diabetes investigation,
Yui Shibayama, and Hiraku Kameda, and Shoichiro Ota, and Kazuhisa Tsuchida, and Kyu Yong Cho, and Akinobu Nakamura, and Hideaki Miyoshi, and Tatsuya Atsumi
January 2017, Oncotarget,
Yui Shibayama, and Hiraku Kameda, and Shoichiro Ota, and Kazuhisa Tsuchida, and Kyu Yong Cho, and Akinobu Nakamura, and Hideaki Miyoshi, and Tatsuya Atsumi
November 2016, Journal of diabetes investigation,
Yui Shibayama, and Hiraku Kameda, and Shoichiro Ota, and Kazuhisa Tsuchida, and Kyu Yong Cho, and Akinobu Nakamura, and Hideaki Miyoshi, and Tatsuya Atsumi
April 2019, Endocrine journal,
Yui Shibayama, and Hiraku Kameda, and Shoichiro Ota, and Kazuhisa Tsuchida, and Kyu Yong Cho, and Akinobu Nakamura, and Hideaki Miyoshi, and Tatsuya Atsumi
October 2019, Journal for immunotherapy of cancer,
Yui Shibayama, and Hiraku Kameda, and Shoichiro Ota, and Kazuhisa Tsuchida, and Kyu Yong Cho, and Akinobu Nakamura, and Hideaki Miyoshi, and Tatsuya Atsumi
October 2016, Acta diabetologica,
Yui Shibayama, and Hiraku Kameda, and Shoichiro Ota, and Kazuhisa Tsuchida, and Kyu Yong Cho, and Akinobu Nakamura, and Hideaki Miyoshi, and Tatsuya Atsumi
January 2020, Journal of diabetes investigation,
Yui Shibayama, and Hiraku Kameda, and Shoichiro Ota, and Kazuhisa Tsuchida, and Kyu Yong Cho, and Akinobu Nakamura, and Hideaki Miyoshi, and Tatsuya Atsumi
January 2021, Frontiers in immunology,
Copied contents to your clipboard!